Evaluation study of ozoyl Rigenoma in the treatment of lesions chronic skin lesions
Accepted: November 21, 2022
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Ozone has been used for medical purposes since the 1800s and has also been used for years to treat skin lesions. The properties of this molecule are many, including increased O2 availability, anti-inflammatory and antiseptic. We tested the performance of an Ozoyl-based preparation (stable Ozonides from organic olive oil) in the treatment of chronic skin lesions. The following were 40 patients with lesions of different aetiology and localisation to the leg or foot were recruited. The parameters analysed were: area infection, pain, WBP and occurrence of adverse events. The observational study comprised a 2-week enrolment and observation run in of 2 weeks and a treatment period with Ozoyl of 6 weeks. The data collected showed an excellent performance of the presidium used on all parameters. The same data, analysed with the linear ANOVA test, showed a p significance on area, pain and occurrence of infection. The authors believe that these results confirm the hypotheses, reported reported in the literature on the activities of ozone and its derivatives.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.